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Clinical Note
Withdrawal-associated injury site pain (WISP):
a descriptive case series of an opioid
cessation phenomenon
Launette Marie Rieba,b,*, Wendy V. Normana, Ruth Elwood Martinc, Jonathan Berkowitzd, Evan Woodb,e,
Ryan McNeilb,e, M.-J. Milloyb,e
Abstract
Withdrawal pain can be a barrier to opioid cessation. Yet, little is known about old injury site pain in this context. We conducted an
exploratory mixed-methods descriptive case series using a web-based survey and in-person interviews with adults recruited from
pain and addiction treatment and research settings. We included individuals who self-reported a past significant injury that was
healed and pain-free before the initiation of opioids, which then became temporarily painful upon opioid cessation—a phenomenon
we have namedwithdrawal-associated injury site pain (WISP). Screening identifiedWISP in 47 people, of whom34 (72%) completed
the descriptive survey, including 21 who completed qualitative interviews. Recalled pain severity scores for WISP were typically high
(median: 8/10; interquartile range [IQR]: 2), emotionally and physically aversive, and took approximately 2 weeks to resolve (median:
14; IQR: 24 days). Withdrawal-associated injury site pain intensity was typically slightly less than participants’ original injury pain
(median: 10/10; IQR: 3), and more painful than other generalized withdrawal symptoms which also lasted approximately 2 weeks
(median: 13; IQR: 25 days). Fifteen surveyed participants (44%) reported returning to opioid use because of WISP in the past.
Participants developed theories about the etiology of WISP, including that the pain is the brain’s way of communicating a desire for
opioids. This research represents the first known documentation that previously healed, and pain-free injury sites can temporarily
becomepainful again during opioid withdrawal, an experiencewhichmay be a barrier to opioid cessation, and a contributor to opioid
reinitiation.
Keywords: Pain, Substance withdrawal syndrome, Opioid, Opioid dependence, Hyperalgesia, Opioid-induced hyperalgesia,
Self-report, Mixed methods
1. Introduction
A growing appreciation of the deleterious effects of short- and
long-term opioid use8,27,38,42,56,57,90,97,99,103,114,122,130 has
spurred the need to address barriers to opioid cessation. Among
these barriers, pain during or right after opioid withdrawal may be
key.82,107 Generalized myalgias and arthralgias are well known to
occur during opioidwithdrawal,53 andwere described as “internal
rheumatism” almost 2 centuries ago.110
It is known that opioid use itself can cause adaptations in the
central nervous system that lead to increasedpain sensitivity, termed
opioid-induced hyperalgesia (OIH),3,6,10,21,32,41,65,68,84,91,92 clinically
first described over a century ago.2 Opioid-induced hyper-
algesia is at times confused with tolerance, which may be
distinct in both mechanism and treatment.6,29,51 Once opioids
are stopped, the pain sensitivity can continue or seem to
heighten temporarily because any pain-relieving effect opioids
may have provided is eliminated, and the drug-opposite effect
can take time to subside.139 Also, in preclinical models, opioid
withdrawal induces central changes in neurotransmitters,
along with neuroimmune and neuroinflammatory mediators
involved in nociception,43,44 thus potentially intensifying pain
beyond OIH. A general increase in pain sensitivity after opioid
cessation can occur after acute4,55 or chronic66,109,132,144
opioid exposure, referred to by a variety of names including
withdrawal-induced hyperalgesia (WIH). For individuals with
chronic noncancer pain (CNCP) or an opioid use disorder
(OUD), severity of pain during and immediately after
opioid withdrawal can be a risk factor for restarting
opioids.17,63,82,107,124 As a result, dose reduction or elimina-
tion can be difficult for those who take opioids, and can create
enormous challenges in the doctor–patient relationship.52
Along with the above pain syndromes, we have observed
patients who report that pain can reoccur at their old, previously
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healed, and previously pain-free injury sites during rapid opioid
cessation, and that this reoccurring pain can resolve once the
opioid withdrawal syndrome is over. To our knowledge, no
previous studies have described such a pain experience.
Qualitative research can supplement quantitative results and
help record new experiences, point to possible etiologies, and
assist with future directions in research and treatment.36
Therefore, we undertook an exploratory mixed-methods study
to document the existence and characteristics of this pain
phenomenon that we have named withdrawal-associated injury
site pain (WISP).
2. Methods
This nonconsecutive exploratory case series was derived from
data gathered through an online survey and semistructured
qualitative interviews using a convergent mixed-methods
design.36,105
We were unable to identify any previously published validated
instruments to assess injury site pain during opioid withdrawal.
Therefore, we created and iteratively tested a pilot survey,
administering it to target populations followed by individual-
focused interviews, until no further changes were required for
external consistency. We developed 5 screening questions and
a descriptive survey containing 35 questions, with some options
for narrative responses. Survey content validity was achieved
through face validation and context validation. The survey literacy
level was assessed to be grade 7.4 on the Flesch–Kincaid
scale.54,79 In the survey given to participants, WISP was referred
to as “recurrent pain” which was updated toWISP in Supplement
1 for congruency with this report (available online as Supplemen-
tal Digital Content at http://links.lww.com/PAIN/A341). Instead of
taking the online survey, participants living close to the research
team could choose an in-person semistructured interview using
online survey questions plus semistructured qualitative questions
to further explore their perceptions and beliefs. The lead author
(L.M. Rieb) conducted all interviews. New questions evolved as
themes and nuances of the WISP experience emerged.
We enrolled a diverse cohort of patients reporting daily opioid
consumption, regardless of the reason they had taken opioids
(CNCP or OUD) because the neurophysiologic changes induced
by opioids that affect withdrawal are likely the same in both
populations.9,62 We recruited a convenience sample using
posters and bookmarks, as well as snowball sampling methods.
Posters purposefully sought participants who had pain at old
injury sites during opioid withdrawal and were placed at 20
facilities across Canada, including inpatient and outpatient
detoxification treatment facilities, out-patient pain management
clinics, primary care methadone clinics, and a local inner-city
research facility, between November 2013 and June 2015.
Interview participants gave written consent to participate. The
University of British Columbia’s Behavioral Ethics Review Board
and the Vancouver Coastal Health Research Institute approved
the study protocol.
Eligible participants were 18 years or older and acknowledged
being able to read English at a grade 8 level or above. Individuals
were excluded from the interview if they appeared impaired from
substance or medication use. The 5 initial screening questions
probed for the presence of WISP:
(1) Use of opioids daily for 3 months or more, and
(2) A significant painful injury that was healed and pain-free for at
least 3 months before starting opioids, and
(3) During that pain-free time was off all other pain medications,
and
(4) Two weeks or more off opioids since starting daily use, and
(5) Temporary return of pain at the old healed injury site when
stopping opioids.
If the participant answered “yes” to all 5 screening questions,
they met criteria for having WISP. These participants could
choose to continue to the additional descriptive survey.
Participants self-administering the online survey were given
options to link to resources for emotional support, to enter a draw
for a gift, and to return to the website later for a copy of the results.
In addition, participants who agreed to be interviewed received
a $20 honorarium. Interview recruitment continued until pre-
dominant theme saturation occurred.
Demographic characteristics of participants included in this
study are summarized using descriptive statistics, reporting
percentages and total counts for dichotomous or categorical
values as well as medians and interquartile range (IQR) for
continuous values. Quantitative frequency analysis was per-
formed on the survey questions using SPSS V.23.
The qualitative interviews were recorded and transcribed.
These qualitative data were thematically coded using NVivo
version 11.1.1 (1707) by the lead author (L.M. Rieb). In analyzing
these qualitative data, both deductive and inductive approaches
were used,19 beginning with themes from the survey and
expanding with themes that emerged from the interviews.
3. Results
During the study period, 58 people completed screening,
including 31 by interview. Among these participants, there were
47whomet criteria forWISP. The average agewas 46 years (IQR:
20). Thirty-four (72%) of these participants went on to complete
the full descriptive survey (23 by interview). Among those
interviewed, 21 answered questions beyond the survey and are
included in the qualitative analysis (2 were excluded for fatigue
and confusion with open-ended questions).
The sociodemographic data of those who completed the full
descriptive survey (along with the subset interviewed) are outlined
in Table 1. For the survey, the median participant age was 45
years (IQR: 18). Most participants were male, white, unemployed,
with a grade 12 education or higher. Most were recruited from an
inner-city research office, followed by primary care clinics that
offered methadone programs, and several from residential
treatment facilities and pain clinics in British Columbia, Canada.
All of the interviews took place in Vancouver. Those interviewed
had similar age and sociodemographic characteristics as the
overall sample.
Interspersed below with the quantitative data are participant
quotes from the themes that emerged during the qualitative
interviews.
3.1. Bodily experiences of withdrawal-associated injury
site pain
Although there was a range of experiences reported, most
participants found WISP to be intense and aversive both
physically and emotionally. As one participant noted, “Oh God, I
was in hell.”
The surveyed descriptive characteristics of the experience of
WISP are outlined in Table 2. Most participants recalled WISP as
being severely painful: The most commonly recalled pain score
for WISP on an 11-point Likert scale (0-10) was 8 (IQR: 2). When
asked to compare intensity of pain, WISP was recalled by most
participants (22; 65%) as being more painful than their
generalized withdrawal pain, and as the same or less painful
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than the original injury, although 13 (38%) felt WISP was even
more painful than their original injury and was often compared
with their original injury in quality. For example, one participant
remarked on WISP being like a “flashback of the original injury”:
“God, it felt just like it did when it was healing when it was
broken, yeah. I don’t know how—any other way to describe it.”
Participant #2, 53 year-old white male, original injury—
fractured arm at age 12
There was often a distinction made between WISP and
generalized withdrawal pain:
“I was pounding my legs…old injury sites are horrendous. So,
like it’s more severe in those spots. The other part you can like
go, get through with a hot cloth, or whatever, with Gravol and
stuff, but old injury sites come back with like, severe severity.”
Participant #17, 58 year old Indigenous female, original
injury—foot fractures requiring plating and lower leg injuries
requiring fasciotomies after a home invasion, capture, and
repeated assault with a hammer.
In the interviews, some participants described potential
inflammatory and neuropathic symptoms of WISP. For example:
“It’s just almost like a shooting up the back ofmy leg, combined
with pressure in that area, as well as, you know, I could feel my
skin stretching and the sensitivity to touch was increased.”
Participant # 5, 35 year old white male, original injury—right
ankle tendon tear requiring casting.
The above engineer also reported swelling of his right (but not
left) ankle during opioid withdrawal. In a variation on this theme,
another participant endorsed always feeling stiffness along with
pain at his old healed injury site:
“Yeah, it was restrictedmotion… I think the texture, the back of
my wrist, I think it became a bit woody and… I deliberately
went through wrist stretching exercises…[to get my] wrist
flexibility back.”—Participant #1, 62 year-old white male
physician, original injury—soft tissue inflammation and in-
fection in the dorsum of his left wrist from injecting fentanyl.
This participant felt WISP and the associated stiffness were
postacute withdrawal phenomena, which occurred temporarily
as withdrawal faded. However, all others interviewed reported
that WISP began during the time of other withdrawal features, but
could extend longer. There was one participant who had no other
opioid withdrawal symptom but pain at his old injury site.
Typically, participants reported that the contralateral area to
the injury site did not hurt in withdrawal or did so in a manner that
was “much, much less, not even notable.” In this regard, the
person acted as their own control, indicating WISP as somehow
distinct from generalized withdrawal pain.
On average, participants noted it took about 2 weeks (median:
14; IQR: 24; range 1-70, with outliers at 120 and 365 days) for
WISP to resolve after stopping opioids. By 30 days, WISP was
finished in 28 (82%) of participants, although for 6 (18%) it lasted
longer than a month.
Table 1
Sociodemographic characteristics.
Age of those with withdrawal-associated injury
site pain (n 5 47)
46; IQR 20
Age of those who took the full survey (n 5 34) 45; IQR 18
Age of those interviewed (n 5 21) 47; IQR 20
Participant characteristics* Survey
(n 5 34), count (%)
Interview
(n 5 21), count (%)
Sex
Male 21 (62) 14 (66)
Female 13 (38) 7 (33)
Race/ethnicity†
White (Caucasian) 24 (72) 13 (62)
Native (First Nations) 9 (27) 7 (33)
Black (African American) 1 (3) 1 (5)
Other 1 (3) 0 (0)
Highest education completed
Grade 11 or less 10 (30) 6 (29)
Grade 12 or equiv. 8 (24) 4 (19)
Trade school 1 (3) 1 (5)
University, college 14 (42) 9 (41)
Missing 1 (3) 1 (5)
Current employment status
Full-time 4 (12) 1 (5)
Part-time 7 (21) 3 (14)
Unemployed 22 (67) 16 (76)
Missing 1 (3) 1 (5)
* Of those that completed the full survey.
† Participants could choose all that applied.
IQR, interquartile range.
Table 2
WISP descriptive characteristics.
Characteristic Count (%) (n 5 34)
WISP at worst (0-10)*
3 1 (3)
4 1 (3)
5 3 (9)
6 6 (18)
7 4 (12)
8 12 (35)
9 1 (3)
10 6 (18)
WISP versus original injury pain†
WISP less painful than injury 16 (47)
WISP same intensity as injury 5 (15)
WISP more painful than injury 12 (35)
Cannot remember 1 (3)
WISP versus general withdrawal pain
WISP less painful than w/d 5 (15)
WISP the same intensity as w/d‡ 4 (12)
WISP more painful than w/d 22 (65)
Cannot remember 3 (9)
How long WISP versus withdrawal
WISP lasted shorter time than w/d 15 (44)
WISP same time as w/d 6 (18)
WISP longer than w/d 13 (38)
WISP makes it harder to stop opioids
Yes 27 (79)
No 7 (21)
WISP makes you want to use opioid
Yes 29 (85)
No 5 (15)
Ever taken an opioid to relieve WISP 15 (44)
* If WISP occurred more than once, participant asked to recall the time WISP was most intense.
† Asked to compare the intensity of the pain.
‡ Included one who did not have withdrawal pain.
WISP, withdrawal-associated injury site pain.
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3.2. Emotional aspects of withdrawal-associated injury
site pain
Participants spoke of the “emotional pain” of opioid withdrawal, in
general, and of WISP, in particular, during which the trauma or
emotional distress associated with the original injury could be re-
experienced. For example:
“There’s also not just physical pain… I was run over by a semi
so I suffered some physical injuries that come up inwithdrawal,
but also there’s anxiety from it too…It’s like PTSD from that big
time”—Participant #8, 38 year old white male with previous
multiple bilateral lower leg and foot fractures after being struck
and pulled underneath a semi-trailer.
3.3. Withdrawal-associated injury site pain affect on opioid
use behavior
Twenty-seven survey participants (79%) felt that having WISP
made it harder to come off opioids, and 29 (86%) reported that
havingWISPmade themwant to take an opioid to relieve the pain.
From the interviews, it was clear that many of our participants had
stopped opioids multiple times, and 15 (44%) of those surveyed
reported having taken an opioid to relieveWISPduring one of their
attempts at detoxification. However, for a few interviewees,
having WISP “…made me glad that I stopped taking opiates.”
3.4. Mitigators of withdrawal-associated injury site pain
There were 19/34 (56%) participants who could recall taking
one or more nonopioid medications or substances that
helped relieve WISP. Most of them (17 [89%]) listed non-
steroidal anti-inflammatory drugs (NSAIDs), most frequent to
least: ibuprofen, naproxen, and ketorolac. Six (32%) men-
tioned acetaminophen, and 3 (16%) listed either gabapentin
or pregabalin. One person each named ketamine, phenobar-
bital, cyclobenzaprine, alcohol, cannabis, and a topical herbal
remedy containing menthol and camphor. Several com-
mented that opioid rotation to buprenorphine before tapering
lessened WISP. One felt rotation to methadone before
detoxification was helpful and another that methadone
maintenance suppressed WISP; however, several partici-
pants remarked that methadone maintenance was the
hardest opioid use to come off of in terms of WISP and
general withdrawal symptoms. A few participants found that
calming techniques assisted in lowering WISP.
Half of those surveyed believed that if they had been told by
a health care provider about WISP they would have “absolutely”
had more courage to get through the opioid cessation process.
3.5. Original injury characteristics
Characteristics of the original injury reported by participants
are listed in Table 3. Participants reported their original injury
usually as having occurred many years before the survey
(median: 17; IQR: 14.5). Fracture was the most commonly
reported type of injury (21 [62%] of cases) at times involving
instrumentation or subsequent infection, followed by soft
tissue injuries (abscesses, strain/sprains, blunt trauma, in-
cision site pain), and one case of dislocation. Most participants
rated the original injury pain as severe: On an 11-point Likert
scale (0-10), themedian pain was 10 (IQR: 3). The original injury
pain typically lasted for weeks or months. Participants reported
that they had a long pain-free span lasting months or, more
commonly, years between their injury and their initiation of
opioids (for a separate issue). The median time between the
original injury and having WISP was 7 years (IQR: 14).
3.6. Opioid withdrawal characteristics
Characteristics of the withdrawal syndrome are listed in Table 4.
The most commonly used opioids before cessation and
experiencing WISP were morphine, heroin, oxycodone, and
methadone. Most participants surveyed had stopped their opioid
use abruptly. Most participants recalled significant opioid
withdrawal symptoms which lasted on average 2 weeks (median:
13 days; IQR: 25; range 2-80 with an outlier at 143). By 30 days,
27 (79%) of the participants were over withdrawal. Nineteen
(56%) survey participants reported restarting opioids to make
generalized withdrawal symptoms go away during one of the
often many attempts at detoxification.
Sixteen of those interviewed recalled the doses of the opioids
used just before stopping and getting WISP. These were
converted to morphine equivalent daily dose (MEDD) and
averaged (Table 5). These high doses are conservative calcu-
lations because we did not include additional opioids used
concurrently if the amount consumed was not recalled.
3.7. Theories about the origin of withdrawal-associated
injury site pain
Participants tried to conceptualize WISP within the context of
their lived experience. Withdrawal-associated injury site pain
was characterized as a “mystery” by some participants.
Furthermore, although there were those who expressed that it
was “all part of the drug withdrawal,” there were others who
reported that they thought they had developed a new disorder,
like “arthritis.” Still other participants believed that they had
improper healing of the original injury, with one participant
noting, “I don’t think it healed right.”
Table 3
Original injury characteristics.*
Characteristic Count (%) (n 5 34)
Type of injury
Fracture 21 (62)
Soft tissue 12 (35)
Other 1 (3)
Original injury pain at worst (0-10)
4 2 (6)
5 2 (6)
6 3 (9)
7 3 (9)
8 2 (12)
9 4 (12)
10 17 (52)
Original injury pain lasted
Days 1 (3)
Weeks 13 (39)
Months 13 (39)
Years 6 (18)
How long pain-free before opioids†
Days 1 (3)
Weeks 5 (15)
Months 10 (30)
Years 17 (52)
* Original injury site.
†Time pain-free at injury site (when off medications and street drugs) before starting opioids.
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One participant combined the view of a possible underlying
injury with lack of endogenous opioids during withdrawal being
the cause of WISP:
“I think [WISP occurs] because lack of my own body producing
a pain killer. That it’s just sensitive due to the injury…Andwhen
I’m in withdrawal my body’s way too sensitive and there’s pain
there that’s not being handled, right… [Then] my body kicks in
its own morphine to cover up because it helps with the, I don’t
know, the tolerance and the damage that’s done there.”
Participant # 8, as above.
A number of interviewees felt that WISP “might be psycholog-
ical.” Another took this concept further and spoke of it as a “ghost
pain.” A more elaborate version of this theme was the concept of
the brain trying to play a trick on the participant as part of drug
craving:
“I thought, okay, it’s such a strong pull to do the drugs that my
brain figured out that because I started taking opiates when I
sprained my ankle, it’s going to start kicking the pain out at the
ankle to get more opiates…because my brain was sub-
consciously craving it… the primal part of my brain, it still wants
to communicate. And it communicates in basic level, right. So
it’s going to be pain, pleasure, pain, pleasure, right… I honestly
do believe it’s a form of communication between the primal
part of your brain and your pre-frontal cortex.” Participant # 5,
as above.
Among those interviewed, a few participants experienced with
multiple withdrawal episodes suggested that it was opioid use
itself that not only produced WISP but after a while could cause
their old healed injury sites to hurt with use:
“In hindsight… I never correlated oxy use to actually producing
pain. And in my experience, that’s pretty much what
happened. Addiction promoted pain.” Participant #10, 34
year-old white female, original injury—minor right knee twist
playing basketball in junior high school.
There was one participant who later had WISP, who identified
that opioid use at the time of his original injury had also seemed to
increase his pain:
“When I got beaten up, when I brokemy tailbone I started using
Tylenol 3s and stuff like that and then it increased it instead.
That was weird.” Participant #18, 39 year-old Indigenous
female, original injury—coccyx fracture from being kicked.
3.8. Current opioid use
At the time of the survey, 21 (61%) participants were no longer
taking opioids, and the rest reported one or more of the following:
Eleven (32%) were in a methadone or buprenorphine/naloxone
maintenance program, 9 (27%) were using opioids because of
addiction, 7 (21%) were using opioids for pain at a different site,
and notably 6 (18%) were taking opioids for pain at the old healed
injury site that they knew could be pain-free after opioid
cessation.
4. Discussion
From the descriptions provided by our participants, the first
clinical picture of WISP has been drawn. For those who have had
a previously healed injury that was pain-free when daily opioids
began, injury site pain can return with a vengeance upon opioid
cessation but vanish like a wisp sometime after withdrawal is
over, an experience that can influence opioid use behavior.
Participants on average rated the intensity of WISP as severe
(8/10), almost as painful as their original injury (10/10), and more
painful than their generalized withdrawal pain. Also some
participants interviewed described neuropathic and inflammatory
symptoms accompanying WISP. The severity of WISP and of the
original injury pain is interesting because there is evidence that an
intense barrage of pain signaling from the periphery, especially if it
involves tissue inflammation, infection, or damage (as with our
subjects), can alter areas of the central nervous system to
become more pain sensitive, a contributor to central
sensitization.12,64,117,140–142
Opioid use can also cause or worsen neuroimmune and
neuroinflammatory responses and add to central sensitization
through the release of prostaglandins, chemokines, and
Table 5
Recalled opioid dose beforewithdrawal-associated injury site
pain WISP.
Calculation (n 5 16) MEDD* (IQR)
Oral route assumed†
Mean 840
Median 213 (970)
Parenteral route assumed‡
Mean 962
Median 480 (1036)
* Morphine equivalent daily dose in milligrams.
† When route not specified, and oral route assumed.
‡ When route not specified, and parenteral assumed.
IQR, interquartile range.
Table 4
Opioid withdrawal characteristics.*
Characteristic Count (%) (n 5 34)
Type of opioid used before cessation†
Morphine 12 (35)
Heroin 12 (35)
Oxycodone 11 (32)
Methadone 10 (29)
Codeine 6 (18)
Hydromorphone 5 (15)
Meperidine 2 (6)
Opioid withdrawal symptoms†
Low mood 33 (97)
Nausea or vomiting 26 (77)
Muscle/joint aches all over 33 (97)
Runny nose/eyes 24 (71)
Wide pupils, goose bumps, and sweat 33 (97)
Diarrhea 28 (82)
Yawning 30 (88)
Fever 21 (62)
Trouble sleeping 31 (91)
Other 15 (44)
None 0 (0)
Method of stopping opioids
Abruptly 16 (47)
Tapering 13 (38)
Rotated opioid to taper 5 (15)
Ever taken an opioid to relieve withdrawal 19 (56)
* At the time they experienced withdrawal-associated injury site pain.
† Participants could choose all that applied.
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cytokines (eg, tumor necrosis factor, substance P, interleukin
2), including those from microglial cells after toll-like receptor
4 stimulation.6,39,60,68,73,80,112,133,134 Along with opioid,
neurokinin 1, and toll-like receptor 4 antagonists, NSAIDS
and gabapentinoids have been found to reduce neuro-
inflammation and mitigate OIH and/or WIH in
some1,5,14,18,34,45,46,61,70,83,85,94,100,121,127,135,137 but not
all50 circumstances. In our study, a subset of participants
named NSAIDs most frequently and gabapentinoids third for
relieving WISP, supporting a possible neuroinflammatory
component.
Additional aspects of central sensitization that have been
implicated in OIH and WIH involve changes in ascending and
descending central pathways (including the dorsal horn, rostral
ventromedial medulla, raphe nucleus, and somatosensory
cortex) and involve gamma-Aminobutyric acid, dynorphin,
cyclic adenosine monophosphate, protein kinase,
glutamate, N-methyl-D-aspartate receptors, and other compo-
nents.13,15,16,22,25,26,39,43,58,86,92,93,98,128,129,145 Among our
participants, just one person each named ketamine, phenobar-
bital, alcohol, and cannabis as relievingWISP. Although these may
be coincidental, there is evidence that these or related substances
may mitigate OIH, WIH, or other forms of pain through modulation
of one of the above mechanisms, some of which are also involved
with gabapentinoids.6,74,94,111,113,116
Anopioid overuse pain syndromehas beenpreviously proposed
that incorporates physical and emotional components driving
opioid use.89 In the narratives reported here, physical pain and
emotional suffering were intertwined during opioid withdrawal and
contributed to the aversive nature of the experience of WISP.
Future research may determine if WISP and potential injury site
swelling may in part be caused by adrenoceptor stimulation from
catecholamine release during opioid withdrawal. This mechanism
has been implicated in WIH.15 Sympathetic outflow, including
anxiety states can modulate neuroinflammation and pain including
joint swelling.106,118 Norepinephrine can also induce glial cells to
release proinflammatory cytokines.60,68 Clinically, both propranolol
and clonidine have been shown to decrease OIH.28,81
Thus, it is speculated that OIH and WIH may play key roles in
WISP: As pain sensitivity increases due to opioid use, and then
further during withdrawal, residual underlying sensitivity from the
injury (either peripheral or central) may be uncovered, exacer-
bated by sympathetic outflow, including anxiety from pain.
Withdrawal-associated injury site pain was typically recalled to
last about 2 weeks, similar to the timing of withdrawal. By 1month,
WISP was resolved in 82% of participants. Previous documenta-
tion has shown that the nervous system takes time to reset after
prolonged opioid exposure.95 Previous heroin users, those
withdrawn from methadone, and patients with chronic low back
pain withdrawn from prescription opioids have all been shown to
have abnormal heat or cold pain perception for somewhere
between one and 5 months after opioid cessation.108,109,126,132
Opioid rotation before taper was reported by a few of our
participants to be helpful. Unfortunately, opioid substitution therapy
has not always been shown to improve OIH in heroin users and
may insteadworsen it,33 although low dosemethadonemay assist
in OIH prevention35 and has been shown to allow pain control in
cancer patients unresponsive to rapid escalation of other opioids.96
Our group reported extensive generalized withdrawal symp-
toms with opioid cessation. Two other studies in CNCP patients
did not find “significant” withdrawal symptoms after opioid
cessation, measuring on average 4 on the Clinical Opiate
Withdrawal Scale (COWS), yet their participants had WIH to cold
or heat pain.66,144 One explanation for the discrepancy may be
that a low COWS score still may be recalled as withdrawal. Other
explanations may include study population differences in initial
opioid dose, duration of opioid use, rate of opioid cessation,
presence of opioid rotation, other medications used during
tapering, and number of times detoxified—all of which have been
shown to influence OIH or WIH.14,24,30,44,47,66,74,104,124,131
Comparatively low opioid doses, along with taper instead of
abrupt cessation may in part explain why a number of studies
have reported a lack of temporary CNCP pain escalation (or even
improvement in pain) immediately after opioid cessa-
tion,11,82,102,125,131 although their dropouts may have had
a different experience. Also, it is unknown in the other studies if
the original source of CNCP was injury.
This study further outlined participant theories regarding the
etiology of WISP. Attribution of WISP to normal withdrawal, or
speculation about re-injury was predicted. However, the idea
that the opioid-dependent brain is sending a pain signal to try to
trick the person to take more opioids was an unexpected
finding. Certainly, craving is a risk factor for relapse.138 Also
evidence exists that pain modulates dopamine release from the
mesolimbic system.123 However, the concept of drug craving
triggering pain has not been previously well documented. This
brings up the possibility that beyond physiologic dependence,
addiction may be a driver for WISP. Also, opioid-induced glial
cell activation can activate systems responsible for drug reward
and dependence.31,68,69,71,101
Some participants had insight that taking opioids may cause or
contribute to WISP, and involve endogenous pain systems.
Perhaps if we had not recruited specifically for thosewho only had
injury site pain during withdrawal, we may have had more
narratives demonstrating a potential link between OIH and WISP.
The vast majority of our participants felt that havingWISPmade
it harder to come off opioids, and made them want to use an
opioid again, which 44% did during one of multiple detoxification
episodes. Although at the time of the survey most participants
were off opioids, it is poignant that almost one-fifth of the
participants had restarted opioids to relieve pain at their old
healed injury site — the one they knew could be pain-free once
they came off. Thus, by implication, they were taking opioids
chronically to relieve WISP (although new pathology is possible).
In general, for those with OUDs pain may be a risk factor for
continued substance use,40,63,107,119 yet the source of the pain is
rarely differentiated,40,78,115 so it is unknown if injury site pain was
playing a role in previous study populations.
There are limitations to our study. First, it was not designed to
measure prevalence. Also, pain intensity and duration may be
subject to recall bias, although reliable and valid in some
circumstances.20,37,120 Technical barriers to online survey self-
completion became apparent so the interview process was
expanded. The principal investigator did all of the interviews and
coding so there is a possibility of investigator and interview bias.143
Information on cigarette smoking status and alcohol cessation
were not elicited yet may influence the success of opioid
elimination67 and add to pain during withdrawal.7,72 We did not
question psychological status, which can affect WIH23 and alter
recalled acute pain intensity59 and opioid utilization48,49 as well as
affect relapse and dropout rateswhen stopping opioids.63,77,88We
did not look at genetic, sex, and hormonal differences, all of which
can impact OIH.75,76,87,136 Finally, we did not recruit controls with
no previous significant injury, although many of our participants
acted as their own control (injury-free on the contralateral side).
This research represents the first known documentation that
previously healed, and pain-free injury sites can temporarily
become painful again when stopping opioids. This experience
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seems to be a barrier to opioid cessation and raises an important
question. Are there patients labeled with CNCP who in fact have
WISP? Given the findings in this study, a prospective observa-
tional cohort study could document WISP incidence, mitigating
factors, influence on opioid detoxification, as well as correlation
with OIH and WIH. Ultimately, a randomized controlled trial of
treatments for WISP could be undertaken to reduce suffering in
those individuals attempting to discontinue opioids.
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